Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase III Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients

NCT02903004 is registered in ClinicalTrials.gov with Fondazione Policlinico Universitario Agostino Gemelli IRCCS as lead sponsor.

NCT NCT02903004
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02903004 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase III Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients
Lead sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase
Phase 3
Overall status
Completed
Start date
April 11, 2016
Completion date
December 20, 2018
Enrollment
242 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian neoplasms